THTobias Henopp

Tobias Henopp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tobias Henopp has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Anja Schmitt

    Department of Surgical Pathology (A.S., P.U.H., A.P.), University Hospital of Zürich, 8091 Zurich, Switzerland

    2 shared publications
  • Aurel Perren

    University of Bern

    2 shared publications
  • Philipp U. Heitz

    Department of Surgical Pathology (A.S., P.U.H., A.P.), University Hospital of Zürich, 8091 Zurich, Switzerland

    2 shared publications
  • Andreas Raffel

    Department of General, Visceral, and Pediatric Surgery (A.R., W.T.K.), University of Düsseldorf, D-40225 Düsseldorf, Germany

    1 shared publication
  • Anne Couvelard

    Bichat-Beaujon Hospitals – AP-HP and Université de Paris

    1 shared publication
  • Attila Zalatnai

    1st Institute of Pathology and Experimental Cancer Research (A.Z.), Semmelweis University, 1085 Budapest, Hungary

    1 shared publication

Latest Publications

  • Open Access

    Glucagon Cell Adenomatosis: A Newly Recognized Disease of the Endocrine Pancreas

    by Tobias Henopp, Martin Anlauf, Anja Schmitt, Regina Schlenger, Attila Zalatnai, Anne Couvelard, Philippe Ruszniewski, Klaus-Peter Schaps, Yvonne M. H. Jonkers, Ernst-Jan M. Speel, et al.

    Background: Glucagon-producing tumors are either solitary neoplasms of the pancreas, occasionally associated with a glucagonoma syndrome, or multiple neoplasms associated with multiple endocrine neoplasia type 1 (MEN1). We observed a previously undescribed multicentric glucagon-producing tumor disease that is not related to MEN1. Methods: Pancreatic tissue from four patients showing multiple neuroendocrine microadenomas and in two cases also macrotumors were screened for hormones using immunohistochemical and morphometric methods. MEN1, von Hippel-Lindau, and p27 germ line and somatic mutation analysis was performed. Deletion of MEN1 (11q13), von Hippel-Lindau (3p25), and the centromere 11 and 3 gene locus was determined by fluorescence in situ hybridization. DNA copy number changes were studied using array comparative genomic hybridization. Results: The pancreatic tissue from the four patients contained more than 870 microadenomas and 10 macrotumors, all of which expressed exclusively glucagon and none of which showed evidence of malignancy. In addition, many islets were unusually large and showed glucagon cell hyperplasia. There was no clinical or molecular evidence of any hereditary tumor disease, and changes in the MEN1 gene were only seen in individual tumors. Array comparative genomic hybridization of one macrotumor and 20 pooled microadenomas revealed a homogeneous diploid chromosome set. Conclusions: The findings are sufficiently distinctive to suggest a new neoplastic disease of the endocrine pancreas that we recommend calling glucagon cell adenomatosis. Clinically, this disease may be an incidental finding, or it may lead to a glucagonoma syndrome.


  • Open Access

    Multiple Endocrine Neoplasia Type 1 (MEN1): Loss of One MEN1 Allele in Tumors and Monohormonal Endocrine Cell Clusters But Not in Islet Hyperplasia of the Pancreas

    by Aurel Perren, Martin Anlauf, Tobias Henopp, Thomas Rudolph, Anja Schmitt, Andreas Raffel, Oliver Gimm, Eberhard Weihe, Wolfram T. Knoefel, Henning Dralle, et al.

    Context: The occurrence of multiple small pancreatic endocrine tumors in patients suffering from multiple endocrine neoplasia type 1 (MEN1) represents a unique possibility to study early neoplasms and their potential precursor lesions. To date, it is unknown whether small islet-like endocrine cell clusters found in MEN1 patients are neoplastic or rather hyperplastic. It is also unclear whether microadenomas develop from islets. Design: We hypothesized that monohormonal endocrine cell clusters observed in MEN1 patients are small neoplasms with loss of heterozygosity of the MEN1 locus. Using a technique combining fluorescence in situ hybridization of the MEN1 locus and the centromeric region of chromosome 11q with hormone immunostaining, we examined resection specimens from four MEN1 patients. We focused our investigations on the following: 1) typical microadenomas; 2) monohormonal endocrine cell clusters; 3) endocrine and exocrine structures entrapped in microadenomas; and 4) morphologically normal islets. Results: Loss of one MEN1 allele was found in all 27 microadenomas and 19 of 20 (95%) monohormonal endocrine cell clusters. By contrast, it was absent in islets and ductal or acinar structures. Our results indicate that monohormonal endocrine cell clusters represent a minute form of microadenomas. Conclusion: The frequent presence of single nonneoplastic insulin cells in microadenomas and the occurrence of microadenomas in islets suggest an islet origin of microadenomas. Islet hyperplasia does not seem to be an obligatory stage in pancreatic MEN1-associated tumor development.